Swedish Neogap and the Zurich-based company Cellerys has entered a collaboration related to Phase II study of a new therapy for multiple sclerosis.
Cellerys will use Neogap’s patented EpiTCer technology in its upcoming Phase II study of a new type of cell therapy aimed at inducing antigen-specific immune tolerance in patients with multiple sclerosis (MS). Neogap’s EpiTCer technology will help detect rare autoreactive T cells in the patients, using them as biomarkers to study if and when patients develop tolerance.
The collaboration with Cellerys opens up opportunities for Neogap to use our technology platform in several disease fields, including autoimmune diseases and other immune-related conditions.”
“We are thrilled to contribute to and be a part of Cellerys upcoming Phase II study, where EpiTCer will be a key aspect in monitoring autoreactive T cells. The collaboration with Cellerys opens up opportunities for Neogap to use our technology platform in several disease fields, including autoimmune diseases and other immune-related conditions. Our goal is to continue to develop innovative applications for EpiTCer and contribute to the development of new therapies for the treatment of severe diseases,” says Samuel Svensson, CEO of Neogap.
The EpiTCer technology has been developed by associate Professor Hans Grönlund, CSO and founder of Neogap.
Cellerys’ therapy RED4MS is a highly innovative approach to fight MS. It has been developed over the past decade and has successfully passed Phase Ib clinical testing. Cellerys is preparing a multi-center Phase IIa trial as the next important milestone to bring RED4MS to patients. The objective of the trial is to demonstrate proof of concept, and Neogap is producing EpiTCer beads for the analysis of the study results.
Photo: Neogap
